Breaks Categories: News

WednesdayNov 01, 2017 10:08 am

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Receives Extensive Patent Allowance from USPTO

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a drug delivery platform innovator, announced late yesterday that it has received a new Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) related to the use of its innovative DehydraTECH™ technology as a delivery platform for the full list of active pharmacological ingredients requested, including all cannabinoids, fat-soluble vitamins, nonsteroidal anti-inflammatory pain medications (“NSAIDs”) and nicotine. The company expects formal patent issuance within three to four months, with provided protections extending through 2035 or later. “This wide-ranging patent allowance from the USPTO exceeds our expectations,” Chris Bunka, chief executive…

Continue Reading

WednesdayNov 01, 2017 9:42 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Announces Three Additions to Board of Directors

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning expanded its board of directors, announcing its appointment of Delray Wannemacher and Patrick Leung as independent directors and Keevin Gillespie as an executive director, effective immediately. Per the update, Wannemacher and Leung will also serve on the company’s audit committee alongside recently appointed chief financial officer Paul Dickman. “We are extremely pleased to welcome Delray, Patrick and Keevin to the ChineseInvestors.com, Inc.'s Board of Directors,” Warren Wang, chief executive officer of ChineseInvestors.com, stated in the news release. “Their financial and industry experience make these gentlemen excellent choices for the Company's Board…

Continue Reading

TuesdayOct 31, 2017 1:55 pm

NetworkNewsBreaks – Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) Closes Equity Financing Deal

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) today confirmed the closing of its recently announced bought deal equity financing. The company sold roughly 9.6 million units at a price of $1.20 each for gross proceeds of $11.523 million. These figures included the 1.25 million units sold pursuant to the full exercise of the underwriters’ over-allotment option. Per the news release, each unit consists of one common share of the company’s Canada-listed stock and one half of one common share purchase warrant. The warrants, which will be listed and posted for trading on the TSX Venture Exchange under the symbol…

Continue Reading

TuesdayOct 31, 2017 12:01 pm

NetworkNewsBreaks – Geron Corp. (NASDAQ: GERN) Shares Surge on FDA Granting Fast Track Designation to Imetelstat for Lower Risk MDS

Shares of Geron (NASDAQ: GERN) are up 6.75% after the company this morning said its telomerase inhibitor, imetelstat, has been granted Fast Track designation by the United States Food and Drug Administration (FDA) to treat adults with transfusion-dependent anemia due to Low or Intermediate-1 risk myelodysplastic syndromes (MDS) who are non-del and who are refractory or resistant to treatment with an erythropoiesis stimulating agent. Geron initially developed imetelstat, which is exclusively licensed to Janssen Biotech, Inc. worldwide. Janssen sponsored the application for Fast Track designation using preliminary data from IMerge, the ongoing clinical trial being conducted by Janssen in lower…

Continue Reading

TuesdayOct 31, 2017 10:33 am

NetworkNewsBreaks – EVIO, Inc. (EVIO) Expands Testing Capabilities at Yuba City Laboratory

EVIO, Inc. (OTCQB: EVIO), a leading provider of cannabis analytical testing services, this morning announced that it has expanded testing capabilities at its Yuba City laboratory in Northern California. The expansion comes in anticipation of California’s new 2018 testing rules and includes a full suite of testing services, such as pesticide, microbiological and expanded cannabinoid potency testing. “We are getting feedback directly from clients on the ground in California that is similar to what we experienced in Oregon back in 2015 when we opened our first lab in Oregon a full year before the official rollout of their testing requirements,”…

Continue Reading

TuesdayOct 31, 2017 10:02 am

NetworkNewsBreaks – Global Payout, Inc. (GOHE) Subsidiary Co-Hosts Cannabis Industry Networking Event

Payment solutions company Global Payout, Inc. (OTC: GOHE) this morning announced that its majority owned subsidiary, MoneyTrac Technology, Inc., successfully hosted a joint networking event last week in Las Vegas with fellow companies operating in the cannabis financial market sector, including Fusion Bank, Integrated Compliance Solutions, LLC and NICCE Exchange. Notably, the event brought together key individuals from different areas across the West Coast who are involved in the fast-growing cannabis industry. “The power of networking and identifying synergistic business opportunities should never be underestimated,” James Hancock, CEO of MoneyTrac Technology, stated in the news release. “From banking solutions to…

Continue Reading

TuesdayOct 31, 2017 9:36 am

NetworkNewsBreaks – Greenkraft, Inc. (GKIT) Announces Entry into Multiple Supply Contracts

Greenkraft, Inc. (OTCQB: GKIT), a nationally recognized player in the alternative fuel engine and vehicle market, this morning announced its entry into supply contracts with several dealers and distributors looking to provide to their customers a range of efficient, eco-friendly commercial trucks. “We continue to see increased and widespread demand for alternative commercial trucks and alternative fuel systems, and we are pleased to be in a position to meet this demand with our line of vehicles,” George Gemayel, CEO of Greenkraft, noted in the news release. “These new supply contracts are on par with our recently announced initiatives to expand…

Continue Reading

MondayOct 30, 2017 2:34 pm

NetworkNewsBreaks – FAT Brands (NASDAQ: FAT) Rings Opening Bell at NASDAQ Following IPO

FAT Brands (NASDAQ: FAT) rang the NASDAQ opening bell this morning following its successful Reg A+ initial public offering (IPO). The offering was launched this summer with a goal of raising $20 million. The IPO closed on Friday, October 27, exceeding its target by raising $24 million through the sale of two million shares priced at $12.00 per share. Operating with its online division BANQ®, TriPoint Global Equities, LLC acted as the lead managing selling agent and sole book runner for the offering. Additionally, the company aims be the first Reg A+ Issuer listed on a National Securities Exchange to…

Continue Reading

MondayOct 30, 2017 1:09 pm

NetworkNewsBreaks – Cardiome Pharma Corp. (NASDAQ: CRME) Initiates Commercial Launch of Xydalba™ in Three European Countries

Cardiome Pharma (NASDAQ: CRME) (TSX: COM) has initiated the commercial launch of Xydalba™ in Sweden, Finland and the Republic of Ireland, per the company’s announcement this morning. The European Medicines Agency (EMA) has approved Xydalba for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in adults. Xydalba was approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of adult patients with ABSSSI caused by susceptible Gram-positive bacteria, including MRSA. "Our geographic footprint continues to expand, allowing us to make our portfolio of differentiated hospital products available to patients through our ex-U.S. global…

Continue Reading

MondayOct 30, 2017 12:10 pm

NetworkNewsBreaks – Aviragen Therapeutics, Inc. (NASDAQ: AVIR) Shares Drop on Merger Agreement with Vaxart, Inc.

Shares of Aviragen Therapeutics (NASDAQ: AVIR) are down 13.24% after the company this morning said it has entered into a definitive merger agreement with Vaxart, Inc., a privately-held company focused on developing oral recombinant vaccines based on its proprietary delivery platform. The combined company created by the merger, Vaxart, Inc., will be focused on developing orally-delivered therapeutics and prophylactics to address various viral infections. “After a comprehensive review of strategic alternatives, we are delighted to announce this transaction with Vaxart, which will complement Aviragen’s focus on infectious diseases and position us to create both near and long-term value for our…

Continue Reading